“Blood markers vs transient elastography for liver stiffness and steatosis in metabolic dysfunction-associated steatotic liver disease “
Post Delphi consensus 2023, MASLD era has opened a Pandora’s box of non biopsy research arenas
Oflate FDA is considering Liver stiffness measurement for drug trials on MASLD, Liver biopsy might not be a mandatory requirement in future.
FB page